Core Viewpoint - Applied Therapeutics, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact investor confidence and the company's market performance [1] Group 1: Company Overview - The lawsuit has been filed against Applied Therapeutics, Inc. by investors who claim that the company misled them regarding its financial health and business prospects [1] - The legal action highlights potential issues in the company's disclosures and compliance with securities regulations, which could lead to financial penalties or reputational damage [1] Group 2: Industry Implications - The case against Applied Therapeutics may set a precedent for how biotech companies communicate with investors, particularly regarding transparency and risk disclosures [1] - Increased scrutiny on securities law compliance in the biotech sector could lead to more rigorous regulatory oversight and impact investor relations across the industry [1]

APLT COURT NEWS: Applied Therapeutics, Inc. Sued for Securities Fraud - Investors that Lost Money are Urged to Contact BFA Law before February 18 Deadline ...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT ...

Investors Who Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class Action - APLT ...

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Applied Therapeutics, Inc. ...

Group 1 - The article discusses a pending class action lawsuit against Applied Therapeutics, Inc. with a lead plaintiff deadline set for February 18, 2025 [1] - The law firm Levi & Korsinsky is reminding investors of their rights and the ongoing legal proceedings related to the company [1] - Investors are encouraged to participate in the class action if they have been affected by the company's actions [1] Group 2 - The class action lawsuit is a significant event for Applied Therapeutics, potentially impacting its stock performance and investor sentiment [1] - The article highlights the importance of the deadline for investors to join the lawsuit, emphasizing the urgency of the situation [1] - Legal actions like this can lead to financial implications for the company, depending on the outcome of the lawsuit [1]

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=123051&from=4CLASS PERIOD: J ...

BENSALEM, Pa., Jan. 14, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN APPLIED THERAPEUTICS, INC. (APLT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE FEBRUARY 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LA ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslr ...

Core Viewpoint - The article discusses a class action lawsuit against Applied Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements and failure to adhere to clinical trial protocols, which led to significant stock price declines following negative FDA responses [1][3][4]. Company Overview - Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel drug candidates for rare diseases, specifically targeting validated molecular pathways [2]. Legal Allegations - The class action lawsuit alleges that during the class period from January 3, 2024, to December 2, 2024, Applied Therapeutics and its executives made false or misleading statements regarding the company's adherence to trial protocols, which posed a risk of FDA rejection of their New Drug Application (NDA) for govorestat [3][4]. - On November 27, 2024, it was revealed that the FDA issued a Complete Response Letter for the NDA, indicating that the application could not be approved in its current form due to clinical application deficiencies, resulting in an over 80% stock price drop over three trading sessions [4]. - On December 2, 2024, Applied Therapeutics disclosed receiving a warning from the FDA regarding issues with electronic data capture and a dosing error, leading to a further decline of more than 26% in stock price over three trading sessions [5]. Class Action Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Applied Therapeutics securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having secured over $6.6 billion for investors in class action cases, and is recognized for obtaining significant recoveries in securities litigation [7].